Search
forLearn
5 / 801 resultslearn Quaternium- 87
learn oligopeptide-71
learn PTT-6®
learn APISCALP™
Research
5 / 66 resultsresearch Testosterone Induces Increase in Aquaporin (AQP)-1, 5, and 7 Expressions in the Uteri of Ovariectomized Rats
Testosterone increases certain proteins in the uterus, reducing fluid volume.
research Effects of testosterone on mean arterial pressure and aquaporin (AQP)-1, 2, 3, 4, 6 and 7 expressions in the kidney of orchidectomized, adult male Sprague-Dawley rats
Testosterone raises blood pressure and changes kidney protein levels.
research The role of aquaporins in polycystic ovary syndrome – A way towards a novel drug target in PCOS
Aquaporins could be new drug targets for treating polycystic ovary syndrome.
research IV Międzynarodowe Sympozjum Studenckich Kół Naukowych Środowisko – Roślina – Zwierzę – Produkt Streszczenia
Custom skincare can be made based on genes, fewer cats in Lublin have FeLV/FIV than national average, and studies also looked at small water bodies, river pollution, guppy growth, toxins in biochars, palm oil issues, and pumpkin seed oil for hair strength.
research Investigating the mechanisms underlying effects of testosterone on blood pressure in normotensive and hypertensive rats / Loh Su Yi
Testosterone raises blood pressure by affecting kidney function and brain gene regulation over time.
Community Join
5 / 1000+ resultscommunity AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Polydopamine Synergizes with Quercetin Nanosystem to Reshape the Perifollicular Microenvironment for Accelerating Hair Regrowth in Androgenetic Alopecia.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.